Jinan, China

Qingmin Wang

This inventor holds 1 USPTO granted patent and 3 published patent applications and 1 EPO patent. Top assignee: Qilu Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qingmin Wang. Retrieved from https://idiyas.com/inventor/qingmin-wang-i7ufd06y

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Qingmin Wang: Innovator in Pharmaceutical Composition

Introduction

Qingmin Wang is a notable inventor based in Jinan, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compositions.

Latest Patents

One of his key patents is titled "A Composition Comprising Aflibercept and a Variant Thereof, and Related Methods and Uses." This patent showcases his expertise in creating effective pharmaceutical solutions.

Career Highlights

Qingmin Wang is associated with Qilu Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development initiatives. His work has contributed to the company's reputation as a leader in the pharmaceutical industry.

Collaborations

He has collaborated with notable colleagues, including Huanlan Zheng and Guijiang Wang, to further enhance the impact of their research and innovations.

Conclusion

Qingmin Wang's contributions to pharmaceutical compositions highlight his role as an innovator in the industry. His work continues to influence advancements in medical treatments and therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…